Abstract
Introduction Sepsis, defined as life-threatening organ dysfunction due to dysregulated host response to infection can result from any infection. In 2017, an estimated 48.9 million incident cases of sepsis and 11.8 million sepsis-related deaths were reported globally. Bacterial infection is the major cause of sepsis. Data about sepsis burden is derived almost exclusively from studies in high-income countries yet mortality from sepsis is disproportionately higher in low- and middle-income countries. We aimed to determine the prevalence of sepsis, bacteriological profile of causes, antimicrobial susceptibility patterns, and in-hospital outcomes among adult medical emergencies presenting to Kiruddu National Referral Hospital in Kampala, Uganda.
Methods We conducted a prospective cohort study between December 2018 and July 2019 in which patients presenting to the medical emergency ward with sepsis were consecutively enrolled; blood was drawn for aerobic blood cultures, antimicrobial susceptibility patterns were determined and patients were followed up for in-hospital outcomes.
Results Of 1,657 patients screened during the study period, 243(14.7%) had sepsis, the median age was 45 years (IQR 32,65) and the majority were female (55.6%). Among patients with sepsis; 46 (18.9%) had positive aerobic blood cultures. Staphylococcus aureus was the most common isolate (31/46, 67.4%) with a predominance of Methicillin-Resistant Staphylococcus aureus (MRSA) (20/31, 64.5%). Of the 243 patients followed up, 143 (58.9%) died in hospital with an average length of stay of 4.9 days (SD 5.5) for those who died and 10.2 (SD 7.6) for those that were discharged alive. None of the patients was admitted to ICU.
Conclusions Sepsis was common (14.7%) among adult medical emergencies and it was associated with a high in-hospital mortality rate (58.9%). Positive blood cultures were predominantly Staphylococcus aureus and nearly a third of these were Methicillin-Resistant.
Competing Interest Statement
The authors have declared no competing interest.
Funding Statement
This study was funded by the MERCK foundation under the MERCK-Makerere Masters in Internal Medicine Scholarship Program under the department of medicine, Makerere University College of Health Sciences. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
Makerere University School of Medicine Research and Ethics Committee (SOMREC)
I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.
Yes
Data Availability
data are not currently available in a public repository but can be availed up on request from the corresponding author
